Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis SpasticityPRNewsWire • 06/28/22
Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual MeetingPRNewsWire • 06/07/22
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep MedicinePRNewsWire • 06/01/22
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA MeetingsPRNewsWire • 05/12/22
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome TherapeuticsPRNewsWire • 05/09/22
Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Jazz Pharmaceuticals (JAZZ) Lags Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/04/22
Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial GuidancePRNewsWire • 05/04/22